EMA approves meds
March 25, 2014
The European Medicines
Agency’s (EMA) Committee for
Medicinal Products for Human
Use has recommended granting
a marketing authorisation for
Vynfinit (vintafolide) for ovarian
cancer, Folcepri (etarfolatide)
and Neocepri (folic acid), Sylvant
(siltuximab) for Castleman’s
disease, Entyvio (vedolizumab) for
the treatment of ulcerative colitis
and Crohn’s disease, Jardiance
(empagliflozin) for the treatment of
type 2 diabetes, Olysio (simeprevir)
for chronic hepatitis C, Revinty
Ellipta (fluticasone furoate /
vilanterol trifenatate) for asthma
and chronic obstructive pulmonary
disease (COPD) and Ebilfumin
(oseltamivir) a generic of Tamiflu,
for the prevention and treatment of
influenza.
The above article was sent to subscribers in Pharmacy Daily's issue from 25 Mar 14To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Mar 14